К содержанию
Dr. Tara EinullaevaMedical oncologist

Diagnosis and tests 9 min

Lung Cancer Biomarker Testing: Which Tests You Need Before Treatment

Which mutations are tested for in lung cancer (EGFR, ALK, ROS1, KRAS and more), why PD-L1 matters, tissue or blood, NGS or PCR, and why waiting can be right.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 16 October 2026

In non-small cell lung cancer (especially adenocarcinoma), before drug treatment starts the tumour is checked for changes in the EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, NTRK and HER2 genes, and the PD-L1 protein is measured. The result decides where to start: with targeted therapy tablets, with immunotherapy or with chemotherapy. That is why it is sometimes better to wait a few weeks for the result than to start “something, anything” straight away.

Who needs molecular testing

Patients often ask me why treatment doesn’t start right after the pathology result. The reason is that non-small cell lung cancer is not one disease but several different ones, and molecular testing is what tells them apart.

Under the ESMO and RUSSCO guidelines, testing is required:

  • in non-squamous cancer — above all adenocarcinoma, and also mixed forms;
  • in inoperable stage III and stage IV, when drug treatment is planned;
  • after curative surgery — to choose post-operative treatment: EGFR is tested in stages I–III, and PD-L1 as well in stages II–III.

In confidently diagnosed squamous cell cancer, molecular testing is usually not done. The exceptions are patients under 50, people who have never smoked or smoked lightly, and cases where the histological type is in doubt. I explain how to tell which type your report shows in my article on how to read a pathology report.

One important detail: neither sex, nor age, nor smoking history lets anyone say in advance whether there is a mutation. So testing is needed for everyone for whom it is indicated by histology and stage, not just for “typical” carriers.

Which mutations are tested for and what they change

Alteration How common What a finding offers
EGFR (mutations) More common in non-smokers, women and people of Asian descent EGFR inhibitor tablets
ALK (rearrangement) About 5%, more common in non-smokers ALK inhibitors
ROS1 (rearrangement) 1–2% ROS1 inhibitors
BRAF V600E BRAF mutations — about 5% (V600E is a subset) BRAF inhibitor + MEK inhibitor
KRAS (including G12C) KRAS — 20–25%, more common in smokers For G12C — KRAS G12C inhibitors
MET (exon 14 skipping) A small percentage MET inhibitors
RET (rearrangement) A small percentage RET inhibitors
NTRK (rearrangement) Rare TRK inhibitors
HER2 (mutations) A small percentage Anti-HER2 drugs

Frequencies are from the American Cancer Society.

For each of these alterations there is a drug that acts specifically on it. I describe how these drugs work and what side effects they have in my article on targeted therapy.

PD-L1: what it is and why it’s measured

PD-L1 is a protein on the surface of cancer cells that the tumour uses to “switch off” the immune cells attacking it. Its level is measured by immunohistochemistry (staining a slice of the tumour) and expressed as the percentage of tumour cells that carry it.

PD-L1 helps estimate how likely immunotherapy is to help. Under the RUSSCO guidelines, in stage IV without driver mutations and with a PD-L1 level of 50% or higher, immunotherapy with a single drug (for example, pembrolizumab) without chemotherapy is an option. At lower levels, immunotherapy is usually combined with chemotherapy.

PD-L1 and mutation testing are not interchangeable — they are two questions, and you need both answers. A high PD-L1 does not cancel the search for mutations: if the tumour has an EGFR mutation or an ALK rearrangement, treatment starts with targeted therapy, not immunotherapy. More on immunotherapy itself in my article on cancer immunotherapy.

Why it’s sometimes worth waiting for the result

Waiting is hard — for patients and for their families. But rushing here has a specific cost.

Immunotherapy works less well with EGFR and ALK. Under the RUSSCO guidelines, in stage IV with an EGFR mutation or ALK rearrangement, treatment starts with targeted therapy. Single-drug immunotherapy is considered only after the standard options have been used up.

The order of treatment affects safety. In a study from Memorial Sloan Kettering, severe immune-related side effects (including lung inflammation — pneumonitis) developed in 15% of patients who received the EGFR inhibitor osimertinib after immunotherapy. In the reverse order — osimertinib first, immunotherapy later — no such complications occurred. Immunotherapy started “before the result” can complicate later targeted treatment.

If you have non-squamous lung cancer and you’re offered immunotherapy before your EGFR and ALK results are back, ask your doctor why you can’t wait. Sometimes there are good reasons, but the question is worth asking.

There are situations when your condition doesn’t allow waiting: marked breathlessness, a fast-growing tumour. Then the decision is made together with your treating doctor, weighing the risks — and that is good medicine too. You can see how such decisions look in practice in the stage IV lung cancer case review.

How long the result takes

The international CAP/IASLC/AMP guidelines set a target of EGFR and ALK results within 10 working days of the sample reaching the laboratory. In practice the time is made up of several steps: requesting the blocks from the archive, sending them, checking whether there are enough tumour cells, and the test itself. If there isn’t enough tissue, a repeat biopsy will be needed — and that takes more time.

What helps speed things up:

  • ask for the material to be sent for molecular testing as soon as non-small cell cancer is confirmed;
  • collect the blocks and slides yourself if the laboratory is at another hospital — check the procedure with your doctor;
  • order all the necessary tests at once rather than one by one.

Tissue or blood, NGS or single tests

Tissue is the main material. Usually it is the paraffin block from the biopsy or surgery — the same one used to make the diagnosis.

Liquid biopsy is a blood test that looks for fragments of tumour DNA. It is used when there is no tissue or a biopsy is too risky, and also at progression, to understand how the tumour has become resistant to treatment. It has one limitation, but an important one: a negative blood result does not rule out a mutation. According to RUSSCO, in about 22% of patients with a negative liquid biopsy the tumour does in fact have a mutation. That is why ESMO recommends testing tissue when the blood test is negative.

Single tests (PCR, IHC, FISH) check one gene or one mutation at a time. They are available in many laboratories and work well when you need an answer on one or two genes, but if they are done one after another, the tissue can run out before all the genes have been checked.

NGS (next-generation sequencing) checks dozens of genes in a single test on one sample. ESMO considers it preferable where available; RNA-based NGS is better for detecting rearrangements (ALK, ROS1, RET, NTRK). RUSSCO recommends at least a mandatory panel — EGFR, ALK, ROS1, BRAF V600E — and using NGS depending on drug availability.

Approach When it fits Limitations
Single tests One or two genes need checking Uses up tissue; rare mutations may go unchecked
NGS panel Stage IV non-squamous cancer, all targets need checking at once Not available in every laboratory
Liquid biopsy No tissue, or biopsy is risky; progression A negative result doesn’t rule out a mutation

Questions to ask your treating doctor

  • What histological type is my tumour, and is molecular testing indicated for me?
  • Which genes were or will be tested — only EGFR and ALK, or the whole panel?
  • Was PD-L1 measured, and what was the result?
  • Is there enough tissue in the blocks, or will I need another biopsy? Can a blood test be done?
  • How long will testing take, and is there a reason to start treatment before the result?
  • If a mutation is found, is the right drug available?

If you were diagnosed recently and aren’t sure whether all the necessary tests have been done, I can review your records in a consultation and help you put together a list of questions for your treating doctor.

Sources

  1. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline — ESMO (Annals of Oncology), 2023
  2. Practical guidelines for drug treatment of non-small cell lung cancer — Russian Society of Clinical Oncology (RUSSCO), 2023
  3. Tests for Lung Cancer — American Cancer Society, 2026
  4. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib — Institut National du Cancer (review of an Annals of Oncology publication), 2019
  5. New Molecular Testing Guideline for Selection of Lung Cancer Patients for Targeted Therapy (CAP/IASLC/AMP) — The ASCO Post, 2013

Frequently asked questions

This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.